Article Details

Citigroup Analysts Give PhaseBio Pharmaceuticals (PHAS) a $27.00 Price Target

Retrieved on: 2019-05-27 18:07:30

Tags for this article:

Click the tags to see associated articles and topics

Citigroup Analysts Give PhaseBio Pharmaceuticals (PHAS) a $27.00 Price Target. View article details on hiswai:

Excerpt

<div><b>Schonfeld Strategic Advisors</b> LLC bought a new stake in PhaseBio Pharmaceuticals during the first quarter valued at $600,000. Finally, Wellington ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up